Don't let a slump in biopharma deals get you down — yet; The controversy on drug prices is taking a toll
Endpoints assesses the big biopharma stories of the week, with a little added commentary on what they mean for the industry.
Hey, what about that big upswing predicted for biopharma M&A?
Dealmakers in biopharma are ending April with a considerable amount of grumbling. This was the year that M&A was supposed to take off, with a new president bullishly asserting plans to reform taxes in a way that would free up billions in Big Pharma cash held overseas.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.